Claims for Patent: 10,022,424

Summary for Patent: 10,022,424

Title:	Use of gelsolin to treat infections
Abstract:	The invention relates to the use of gelsolin to treat infections and to monitor the treatment of infections. The invention also provides methods up-regulating interleukin expression and methods for down-regulating pro-inflammatory cytokine expression.
Inventor(s):	Stossel; Thomas P. (Belmont, MA), Lee; Po-Shun (Boston, MA)
Assignee:	The Brigham and Women\'s Hospital, Inc. (Boston, MA)
Application Number:	11/129,670
Patent Claims:	1. A method for treating an infection in a subject having an infection comprising: administering to a subject having an infection and in need of an increased blood level of gelsolin for the treatment of the infection an effective amount of cytoplasmic gelsolin (cGSN) or plasma gelsolin (pGSN) to increase the blood level of gelsolin to treat the infection, wherein the infection is caused by a gram-positive bacterium, an acid-fast bacillus, a spirochete, an actinomycete, a virus, a fungus, a parasite, Ureaplasma species, Mycoplasma species, Chlamydia species, or Pneumocystis species. 2. The method of claim 1, wherein the gelsolin is pGSN. 3. The method of claim 1, wherein the gram-positive bacterium is selected from the group consisting of Staphylococcus species, Streptococcus species, Bacillus anthracis, Corynebacterium species, Diphtheroids species, Listeria species, Erysipelothrix species and Clostridium species. 4. The method of claim 1, wherein the acid-fast bacillus is a Mycobacterium species. 5. The method of claim 1, wherein the spirochete is selected from the group consisting of Treponema species, Borrelia species, and Leptospira species. 6. The method of claim 1, wherein the virus is selected from the group consisting of Retro viruses, human immunodeficiency viruses, Cytomegaloviruses, Picorna viruses, Polio viruses, hepatitis A virus, enteroviruses, Coxsackie viruses, rhinoviruses, echoviruses, Calciviruses, Toga viruses, equine encephalitis viruses, rubella viruses, Flaviviruses, dengue viruses, encephalitis viruses, yellow fever viruses, coronaviruses, Rhabdoviruses, vesicular stomatitis viruses, rabies viruses, Filoviruses, ebola virus, Paramyxo viruses, parainfluenza viruses, mumps virus, measles virus, respiratory syncytial virus, Orthomyxoviruses, influenza viruses, Hantaan viruses, bunga viruses, phleboviruses, Nairo viruses, Arena viruses, hemorrhagic fever viruses, reoviruses, orbiviruses, rotaviruses, Birnaviruses, Hepadnaviruses, Hepatitis B virus, parvoviruses, Papovaviruses, papilloma viruses, polyoma viruses, Adenoviruses, Herpes viruses, varicella zoster virus, Pox viruses, variola viruses, vaccinia viruses, Iridoviruses, African swine fever viruses, delta hepatitis virus, non-A, non-B hepatitis virus, Hepatitis C, Norwalk viruses, astroviruses, and unclassified viruses. 7. The method of claim 1, wherein the fungus is selected from the group consisting of Cryptococcus species, Histoplasma species, Coccidioides species, Paracoccidioides species, Blastomyces species, Chlamydia species, Candida species, Sporothrix species, Aspergillus species, and fungi of mucormycosis. 8. The method of claim 1, wherein the parasite is selected from the group consisting of Plasmodium species, Toxoplasma species, Babesia species, Leishmania species, and Trypanosoma species. 9. The method of claim 1, wherein the gelsolin is administered orally, sublingually, buccally, intranasally, intravenously, intramuscularly, intrathecally, intraperitoneally, subcutaneously, intradermally, topically, rectally, vaginally, intrasynovially or intravitreously. 10. A method for treating an infection in a subject having a gram-negative bacterial infection comprising: administering to a subject having a gram-negative bacterial infection and in need of an increased blood level of gelsolin for the treatment of the infection an effective amount of cytoplasmic gelsolin (cGSN) or plasma gelsolin (pGSN) to increase the blood level of gelsolin to treat the gram-negative bacterial infection, at a time subsequent to exposure to the infection. 11. The method of claim 10, wherein the gram-negative bacterial infection is caused by Neisseria species, Branhamella species, Escherichia species, Enterobacter species, Proteus species, Pseudomonas species, Klebsiella species, Salmonella species, Shigella species, Serratia species, Acinetobacter species, Haemophilus species, Brucella species, Yersinia species, Francisella species, Pasteurella species, Vibrio cholerae, Flavobacterium species, Pseudomonas species, Campylobacter species, Bacteroides species, Fusobacterium species, Calymmatobacterium species, Streptobacillus species, or Legionella species. 12. The method of claim 10, wherein the gelsolin is pGSN. 13. The method of claim 10, wherein the gelsolin is administered orally, sublingually, buccally, intranasally, intravenously, intramuscularly, intrathecally, intraperitoneally, subcutaneously, intradermally, topically, rectally, vaginally, intrasynovially, or intravitreously. 14. The method of claim 10, wherein the gelsolin is administered at least about one hour after exposure to the infection. 15. A method for treating a subject having an infection comprising: administering cytoplasmic gelsolin (cGSN) or plasma gelsolin (pGSN) with a therapeutic agent to a subject having an infection and in need of an increased blood level of gelsolin, in an effective amount to treat the infection, wherein the infection is caused by a gram-positive bacterium, a gram-negative bacterium, an acid-fast bacillus, a spirochete, an actinomycete, a virus, a fungus, a parasite, Ureoplasma species, Mycoplasma species, Chlamydia species, or Pneumocystis species, wherein the subject is otherwise free of indications calling for treatment with gelsolin. 16. The method of claim 15, wherein the therapeutic agent is an anti-infective agent. 17. The method of claim 16, wherein the anti-infective agent is an anti-bacterial agent, an anti-viral agent, an anti-fungal agent, or anti-protozoal agent. 18. The method of claim 15, wherein the therapeutic agent is an antibiotic. 19. A method for treating a subject at risk of developing an infection comprising: administering cytoplasmic gelsolin (cGSN) or plasma gelsolin (pGSN) to a subject at risk of developing an infection and in need of such a treatment in an effective amount to increase a blood level of gelsolin to prevent the infection that may be caused by a gram-positive bacterium, a gram-negative bacterium, an acid-fast bacillus, a spirochete, an actinomycete, a virus, a fungus, a parasite, Ureoplasma species, Mycoplasma species, Chlamydia species, or Pneumocystis species, wherein the gelsolin is administered prior to exposure of the subject to the infection, and wherein the subject is otherwise free of indications calling for treatment with gelsolin. 20. A method for treating an infection in a subject having a gram-positive bacterial infection comprising: administering to a subject having a gram-positive bacterial infection and in need of an increased blood level of gelsolin for the treatment of the gram-positive bacterial infection an effective amount of cytoplasmic gelsolin (cGSN) or plasma gelsolin (pGSN) to increase the blood level of gelsolin to treat the gram-positive bacterial infection, wherein the cGSN or pGSN is administered to the subject at a time subsequent to exposure to the gram-positive bacterial infection. 21. The method of claim 20, further comprising administering a therapeutic agent to the subject with the gelsolin. 22. The method of claim 1, wherein the gram-positive bacterium is Staphylococcus species. 23. The method of claim 1, wherein the gram-positive bacterium is Streptococcus species. 24. The method of claim 1, wherein the gram-positive bacterium is Bacillus anthracis. 25. The method of claim 1, wherein the gram-positive bacterium is Corynebacterium species. 26. The method of claim 1, wherein the gram-positive bacterium is Diphtheroids species. 27. The method of claim 1, wherein the gram-positive bacterium is Listeria species. 28. The method of claim 1, wherein the gram-positive bacterium is Erysipelothrix species. 29. The method of claim 1, wherein the gram-positive bacterium is Clostridium species. 30. The method of claim 1, wherein the gelsolin is administered orally. 31. The method of claim 1, wherein the gelsolin is administered intravenously. 32. The method of claim 1, wherein the gelsolin is administered intramuscularly. 33. The method of claim 1, wherein the gelsolin is administered subcutaneously. 34. The method of claim 1, wherein the gelsolin is administered topically. 35. The method of claim 20, wherein the gelsolin is pGSN. 36. The method of claim 1, wherein the subject is otherwise free of indications calling for treatment with gelsolin. 37. The method of claim 10, wherein the subject is otherwise free of indications calling for treatment with gelsolin. 38. The method of claim 15, wherein the subject is otherwise free of indications calling for treatment with gelsolin. 39. The method of claim 20, wherein the subject is otherwise free of indications calling for treatment with gelsolin.

Details for Patent 10,022,424

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821	11/12/1998		2024-05-12